Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for subcutaneous use. It provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate ovarian follicular development and estrogen production in women with infertility.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Menopur is a gonadotropin used in reproductive medicine to support follicular growth and ovulation. - Induction of ovulation in women with anovulation: promotes the development of a dominant follicle to achieve ovulation. - Controlled ovarian stimulation for assisted reproductive technology (IVF): enables the growth of multiple follicles to increase the number of retrievable oocytes. - Treatment of hypogonadotropic hypogonadism: replaces deficient endogenous gonadotropins to restore normal ovarian function.

Menopur may be associated with a range of adverse reactions, most of which are related to ovarian stimulation and injection site responses.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal bloating: transient abdominal distension. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness. - Ovarian hyperstimulation syndrome (mild): excessive ovarian response causing fluid shifts.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, shortness of breath, and possible hospitalization. - Thromboembolic events: rare clot formation in veins or arteries. - Allergic reaction: rash, itching, or anaphylaxis. - Multiple pregnancy: increased risk of twins or higher-order gestations.

When using Menopur, clinicians should consider several safety measures to minimise risks. - Patient selection: assess for contraindications such as ovarian cysts or uncontrolled thyroid disease. - Monitoring: perform regular ultrasound and estradiol assessments to detect excessive ovarian response. - Dose adjustment: modify dosage based on individual response and ovarian reserve. - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Storage: Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Menopur may interact with other medications that affect ovarian response or hormone metabolism.

Major Interactions (Avoid): - GnRH agonists used for down‑regulation: may blunt the intended ovarian stimulation. - High‑dose estrogen therapy: can interfere with follicular development.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of ovarian hyperstimulation‑related thrombosis. - Thyroid hormone replacement: altered hormone levels may affect response. - Corticosteroids: may modify ovarian response and fluid balance.